N-[3-[3-[3-[3-[3-[5-[3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]-2-methylpropoxy]propanoylamino]propyl]-5-[3-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[3-[3-[3-[3-[3-[5-[3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]-2-methylpropoxy]propanoylamino]propyl]-5-[3-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanamide
• 化学式: C₅₆H₁₀₅N₉O₂₃
• 分子量: 1272.5
• InChiKey: DZVHIPUMKJCNAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -8
• 重原子数：
  88
• 可旋转键数：
  48
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  498
• 氢给体数：
  17
• 氢受体数：
  26

文献信息

• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：MANOHARAN Muthiah

  公开号：US20120136042A1

  公开（公告）日：2012-05-31

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula (I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.
• ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20140179768A1

  公开（公告）日：2014-06-26

  The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
• POLYNUCLEOTIDE AGENTS TARGETING AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) AND USES THEREOF
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20170204418A1

  公开（公告）日：2017-07-20

  The invention relates to polynucleotide agents, e.g., antisense polunucleotide agents, targeting the ALAS1 gene, and methods of using such agents to alter (e.g., inhibit) expression of ALAS1 and to treat ALAS1 associated diseases, e.g., porphyria.
• COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20170253874A1

  公开（公告）日：2017-09-07

  The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
• PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20170340661A1

  公开（公告）日：2017-11-30

  The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.